Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas

Omura, Takaki; Takahashi, Manabu; Ohno, Makoto; Miyakita, Yasuji; Yanagisawa, Shunsuke; Tamura, Yukie; Kikuchi, Miyu; Kawauchi, Daisuke; Nakano, Tomoyuki; Hosoya, Tomohiro; Igaki, Hiroshi; Satomi, Kaishi; Yoshida, Akihiko; Sunami, Kuniko; Hirata, Makoto; Shimoi, Tatsunori; Sudo, Kazuki; Okuma, Hitomi Sumiyoshi; Yonemori, Kan; Suzuki, Hiromichi; Ichimura, Koichi; Narita, Yoshitaka

doi:10.3390/cancers14102454

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advantage of a comprehensive genomic profiling (CGP) test is the simultaneous analysis of the MSI status, genomic aberrations, and the TMB in solid tumors. A cohort study that used the F1CDx test for diffuse glioma reported that most of the glioblastoma indicated MSS despite a high TMB score [ 18 ]. However, another study demonstrated that the accuracy of an NGS-based MSI analysis is not perfect [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and therapeutic challenges of glioblastoma as an initial malignancy of constitutional mismatch repair deficiency (CMMRD): two case reports and a literature review

et al. 2023

View full text Add to dashboard Cite

Background Constitutional mismatch repair deficiency (CMMRD) results from a biallelic germline pathogenic variant in a mismatch repair (MMR) gene. The most common CMMRD-associated malignancies are brain tumors; an accurate diagnosis is challenging when a malignant brain tumor is the only tumor at presentation. We describe two cases of glioblastoma as the initial CMMRD malignancy and discuss current diagnostic and therapeutic challenges. Case presentation Two children with brain tumors without remarkable family history had biallelic pathogenic germline variants in PMS2. Patient 1: A 6-year-old girl presented biallelic PMS2 germline pathogenic variants. Glioblastomas at the left frontal lobe and right temporal lobe were resistant to immune-checkpoint inhibitor, temozolomide, and bevacizumab. Patient 2: A 10-year-old boy presented biallelic PMS2 germline variants. His glioblastoma with primitive neuroectodermal tumor-like features responded to chemoradiotherapy, but he developed advanced colon cancer and acute lymphocytic leukemia. In both patients, only a monoallelic PMS2 germline variant was detected by conventional gene tests. PMS2 immunohistochemistry showed lack of staining at both the tumors and normal tissue as vascular endothelial cells. Further gene tests revealed large genomic deletion including the entire PMS2 gene, confirming biallelic PMS2 germline variants. Conclusion Conventional multi-gene panel tests are insufficient for detecting large deletions of MMR genes, resulting in misdiagnoses of CMMRD as Lynch syndrome. PMS2 variants have low cancer penetrance; family histories may thus be absent. Long-range gene analyses or immunohistochemical staining of MMR proteins in normal tissue should be considered for pediatric brain tumors with a single allele MMR variant when CMMRD is suspected.

show abstract

Section: Discussionmentioning

confidence: 99%